首页> 外文OA文献 >Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis
【2h】

Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis

机译:使用计算机图像分析鉴定mUm1作为滤泡性淋巴瘤的预后免疫组织化学标记物

摘要

Detection of MUM1+ cells in follicular lymphoma (FL) tissues was previously found to be associated with poor prognosis in a single report, whereas the usefulness of Ki-67 immunostaining remains debated. Our goal was to establish whether these markers have predictive value for patients with FL. We analyzed MUM1 and Ki-67 expression using immunohistochemistry in biopsy samples from 434 patients from the PRIMA randomized trial. The MUM1 prognostic value was then validated in a cohort of 138 patients from the FL2000 randomized trial, using the optimal cutoff value obtained from the PRIMA cohort. The surface of positive staining was quantified using computerized image analysis. In the PRIMA cohort, both high levels of MUM1 positivity (cutoff value of 0.80%) and high levels of Ki-67 positivity (cutoff value of 10.25%) were significantly associated with a shorter progression-free survival (PFS) (P = .004 and P = .007 for MUM1 and Ki-67, respectively). In a multivariate Cox proportional hazards regression model, only MUM1 retained a statistical significance (hazards ratio 1.56; 95% confidence interval, 1.02-2.37; P = .038) after adjustment for the maintenance arm of treatment and the follicular lymphoma international prognostic index score. In the FL2000 cohort, high levels of MUM1 positivity were significantly associated to a shorter PFS (P = .004) and to a trend toward a shorter overall survival (P = .043). This remained significant using a multivariate Cox regression model after adjustment for the follicular lymphoma international prognostic index and the treatment arm for PFS (P = .016). These results show that MUM1 is a strong and robust predictive immunohistochemical marker in patients with FL.
机译:在单个报告中,先前发现在滤泡性淋巴瘤(FL)组织中检测MUM1 +细胞与预后不良有关,而Ki-67免疫染色的有用性仍存在争议。我们的目标是确定这些标志物是否对FL患者具有预测价值。我们使用免疫组织化学分析了来自PRIMA随机试验的434例患者的活检样本中的MUM1和Ki-67表达。然后,使用从PRIMA队列获得的最佳临界值,在FL2000随机试验的138名患者队列中验证了MUM1的预后价值。使用计算机图像分析对阳性染色的表面进行定量。在PRIMA队列中,高水平的MUM1阳性(临界值为0.80%)和高水平的Ki-67阳性(临界值为10.25%)都与较短的无进展生存期(PFS)显着相关(P =。对于MUM1和Ki-67,分别为004和P = .007)。在多变量Cox比例风险回归模型中,只有MUM1在调整了维持治疗方案和滤泡性淋巴瘤国际预后指标得分后,仍保持统计学显着性(危险比1.56; 95%置信区间1.02-2.37; P = .038)。 。在FL2000队列中,高水平的MUM1阳性与较短的PFS(P = .004)和总体生存期较短的趋势(P = .043)显着相关。在调整滤泡性淋巴瘤国际预后指标和PFS治疗组后,使用多变量Cox回归模型仍然具有显着意义(P = .016)。这些结果表明,MUM1是FL患者强而有力的预测免疫组织化学标记。

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号